- Home
- PRG vs RCKT Comparison
PRG vs RCKT Comparison
Compare PRG & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRG | RCKT |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 340.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PRG | RCKT |
|---|---|---|
| Price | $30.44 | $3.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $37.50 | $29.12 |
| AVG Volume (30 Days) | 596.7K | ★ 1.9M |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ 10.59 | N/A |
| EPS | ★ 3.96 | N/A |
| Revenue | ★ $2,507,179,000.00 | N/A |
| Revenue This Year | $1.24 | N/A |
| Revenue Next Year | $7.02 | N/A |
| P/E Ratio | $7.53 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $23.50 | $2.19 |
| 52 Week High | $44.43 | $13.30 |
Technical Indicators
Market Signals| Indicator | PRG | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 56.14 |
| Support Level | $29.07 | $3.36 |
| Resistance Level | $30.76 | $3.64 |
| Average True Range (ATR) | 0.74 | 0.18 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 62.56 | 78.12 |
Price Performance
Historical ComparisonAbout PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.